First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17-Reference-Cited by-同舟云学术

First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17

Published:2024-03 Issue: Volume:200 Page:113600
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Mark Michael,Froesch Patrizia,Gysel Katrin,Rothschild Sacha I.,Addeo Alfredo,Ackermann Christoph J.,Chiquet Sabrina,Schneider Martina,Ribi Karin,Maranta Angela Fischer,Bastian Sara,von Moos Roger,Joerger Markus,Früh Martin

Funder

Krebsliga Schweiz

Swiss Cancer Research Foundation

AstraZeneca

Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung

Staatssekretariat für Bildung, Forschung und Innovation

Astra Zeneca R&D Osaka

Publisher

Elsevier BV

Reference40 articles.

1. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater;Reck;J Clin Oncol,2019

2. IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC;Spigel;Ann Oncol,2019

3. Hendriks L.E. , Kerr K.M. , Menis J. , Mok T.S. , Nestle U. , Passaro A. , et al. . Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Published: January 17, 2023. https://doi.org/10.1016/j.annonc.2022.12.013.

4. Govindan R., Garfield D.H.. Treatment approaches in patients with advanced non-small cell lung cancer and poor performance status. Semin Oncol 31(Suppl 11): 27–31. https://doi.org/10.1053/j.semin oncol.2004.10.006.

5. Non small cell lung cancer patients with ECOG PS2: unsolved questions and lessons from clinical trials;Gebbia;Ann Oncol,2005